Phase I/II study of bisantrene in childhood cancer: a report from the Childrens Cancer Study Group.
A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respectively. The dose limiting toxicities were hepatic and hematologic. One patient with ALL achieved a complete remission and partial responses were observed in three patients with soft-tissue sarcomas. The data indicate that bisantrene, at the doses and schedule used in this study, has limited antitumor activity in pretreated children with cancer.
Movassaghi
N
N
Children's Hospital National Medical Center, Washington, D.C.
Krivit
W A
WA
Krailo
M D
MD
Hammond
G D
GD
D000293:Adolescent; D000328:Adult; D000873:Anthracenes / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D008297:Male
D000873:Anthracenes; C031404:bisantrene